抑郁症是全球疾病负担最重的精神障碍之一，其临床治疗目前仍面临治疗反应率低和传统药物不良反应较多等挑战。近年来，微生物-肠-脑轴（microbiota-gut-brain axis，MGBA）研究的进展表明，肠道菌群及其生物活性代谢产物可通过整合神经-内分泌-免疫通路，对神经系统功能起到关键调控作用，为抑郁症干预提供了新靶点。通过对可调节肠道菌群的天然多糖及其改善抑郁症的研究进行综述，系统阐释多糖经由MGBA介导的多模式抗抑郁机制，为推进抑郁症防治策略提供新见解。

Depression is one of the most burdensome mental disorders worldwide, and its clinical management still faces challenges such as low treatment response rates and frequent adverse effects associated with conventional pharmacological agents. Recent advances in the study of microbiota-gut-brain axis (MGBA) have revealed that gut microbiota and their bioactive metabolites play a key regulatory role in neurological function by integrating neuro-endocrine-immune pathways, thereby offering novel targets for intervention in depression. This review summarizes current research on natural polysaccharides that modulate the gut microbiota and alleviate depression, systematically elucidating the multi-modal antidepressant mechanisms mediated via MGBA, and provides new insights for advancing strategies for the prevention and treatment of depression.

R285

新疆维吾尔自治区自然科学基金（2023D01C238）